Investing.com - Bristol-Myers Squibb (NYSE: BMY) reported second quarter EPS of $1.75, $0.23 worse than the analyst estimate of $1.98. Revenue for the quarter came in at $11.2B versus the consensus estimate of $11.81B.
Guidance
Bristol-Myers Squibb sees FY 2023 EPS of $7.35-$7.65 versus the analyst consensus of $7.99.
Bristol-Myers Squibb's stock price closed at $63.41. It is down -5.03% in the last 3 months and down -15.11% in the last 12 months.
Bristol-Myers Squibb saw 1 positive EPS revisions and 17 negative EPS revisions in the last 90 days. See Bristol-Myers Squibb's stock price’s past reactions to earnings here.
According to InvestingPro, Bristol-Myers Squibb's Financial Health score is "great performance".
Check out Bristol-Myers Squibb's recent earnings performance, and Bristol-Myers Squibb's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar